Northland initiated coverage of Connect Biopharma (CNTB) with an Outperform rating and $7.50 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTB:
- Connect Biopharma Ends ADS Agreement with Deutsche Bank
- Connect Biopharma plans to terminate ADR program, list shares on Nasdaq
- Connect Biopharma Regains Nasdaq Compliance
- Connect Biopharma regains Nasdaq compliance
- Connect Biopharma Holdings: A Promising Investment with Strategic Drug Developments and Strong Financial Position